ApoE ϵ4 is associated with cognition, brain integrity, and atrophy in HIV Over Age 60

Journal of Acquired Immune Deficiency Syndromes

Volumn 73, Issue 4, 2016, Pages 426-432

  Wendelken, Lauren A ^a   Jahanshad, Neda ^b   Rosen, Howard J ^a   Busovaca, Edgar ^a   Allen, Isabel ^a   Coppola, Giovanni ^c   Adams, Collin ^a   Rankin, Katherine P ^a   Milanini, Benedetta ^a   Clifford, Katherine ^a   Wojta, Kevin ^c   Nir, Talia M ^b   Gutman, Boris A ^b   Thompson, Paul M ^b   Valcour, Victor ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acquired Immune Deficiency Syndrome; aging; AIDS dementia Complex; ApoE; cognition disorders

Indexed keywords

APOLIPOPROTEIN E4; GENOMIC DNA; VIRUS RNA; APOE PROTEIN, HUMAN; APOLIPOPROTEIN E;

ADULT; AGE; AGED; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; BRAIN STEM; CD4 LYMPHOCYTE COUNT; COGNITION; CONTROLLED STUDY; CORPUS CALLOSUM; CROSS-SECTIONAL STUDY; DIFFUSION TENSOR IMAGING; DISEASE DURATION; EXECUTIVE FUNCTION; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SEX DIFFERENCE; THALAMUS; WHITE MATTER; ATROPHY; BRAIN; BRAIN DISEASE; COMPLICATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; PHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; APOLIPOPROTEINS E; ATROPHY; BRAIN; BRAIN DISEASES; COGNITION; GENE EXPRESSION REGULATION; GENOTYPE; HIV INFECTIONS; HUMANS; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS;

EID: 84969916798     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000001091     Document Type: Article

References (41)

1. Mateen FJ, Mills EJ. Aging and HIV-related cognitive loss. JAMA. 2012; 308: 349-350.
2. CDC. Centers for Disease Control and Prevention. HIV Surveillance Report. Vol 25. Available at: http://www.cdc.gov/hiv/pdf/g-l/hiv-surveillance-report-vol-25.pdf Published February 2015. Accessed October 2015. 2015.
3. CDC. Centers for Disease Control and Prevention. HIV Surveillance Report. Vol 21. Available at: http://www.cdc.gov/hiv/topics/surveillance/.resources/reports/.- surveillance; Published February 2011. Accessed August 2011. 2009.
4. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008; 372: 293-299.
5. Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-Associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010; 75: 2087-2096.
6. Kawas C, Gray S, Brookmeyer R, et al. Age-specific incidence rates of Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology. 2000; 54: 2072-2077.
7. Ziegler-Graham K, Brookmeyer R, Johnson E, et al. Worldwide variation in the doubling time of Alzheimer's disease incidence rates. Alzheimers Dement. 2008; 4: 316-323.
8. Liu CC, Kanekiyo T, Xu H, et al. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013; 9: 106-118.
9. Caselli RJ, Reiman EM, Osborne D, et al. Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele. Neurology. 2004; 62: 1990-1995.
10. Farlow MR, He Y, Tekin S, et al. Impact of APOE in mild cognitive impairment. Neurology. 2004; 63: 1898-1901.
11. Horsburgh K, McCarron MO, White F, et al. The role of apolipoprotein E in Alzheimer's disease, acute brain injury and cerebrovascular disease: evidence of common mechanisms and utility of animal models. Neurobiol Aging. 2000; 21: 245-255.
12. Busch RM, Lineweaver TT, Naugle RI, et al. ApoE-epsilon4 is associated with reduced memory in long-standing intractable temporal lobe epilepsy. Neurology. 2007; 68: 409-414.
13. Lu PH, Thompson PM, Leow A, et al. Apolipoprotein E genotype is associated with temporal and hippocampal atrophy rates in healthy elderly adults: a tensor-based morphometry study. J Alzheimer's Dis. 2011; 23: 433-442.
14. Panos SE, Hinkin CH, Singer EJ, et al. Apolipoprotein-E genotype and human immunodeficiency virus-Associated neurocognitive disorder: the modulating effects of older age and disease severity. Neurobehav HIV Med. 2013; 5: 11-22.
15. Corder EH, Robertson K, Lannfelt L, et al. HIV-infected subjects with the E4 allele for APOE have excess dementia and peripheral neuropathy. Nat Med. 1998; 4: 1182-1184.
16. Burt TD, Agan BK, Marconi VC, et al. Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression. Proc Natl Acad Sci U S A. 2008; 105: 8718-8723.
17. Hqoare J, Westgarth-Taylor J, Fouche JP, et al. Relationship between apolipoprotein E4 genotype and white matter integrity in HIV-positive young adults in South Africa. Eur Arch Psychiatry Clin Neurosci. 2013; 263: 189-195.
18. Valcour V, Shikuma C, Shiramizu B, et al. Age, apolipoprotein E4, and the risk of HIV dementia: the Hawaii Aging with HIV Cohort. J Neuroimmunol. 2004; 157: 197-202.
19. Morgan EE, Woods SP, Letendre SL, et al. Apolipoprotein E4 genotype does not increase risk of HIV-Associated neurocognitive disorders. J Neurovirol. 2013; 19: 150-156.
20. Cooley SA, Paul RH, Fennema-Notestine C, et al. Apolipoprotein E epsilon4 genotype status is not associated with neuroimaging outcomes in a large cohort of HIV+ individuals. J Neurovirol. 2016. doi: 10.1007/.s13365-016-0434-7.
21. Becker JT, Martinson JJ, Penugonda S, et al. No association between Apoe4 alleles, HIV infection, age, neuropsychological outcome, or death. J Neurovirol. 2015; 21: 24-31.
22. Chiao S, Rosen HJ, Nicolas K, et al. Deficits in self-Awareness impact the diagnosis of asymptomatic neurocognitive impairment in HIV. AIDS Res Hum Retroviruses. 2013; 29: 949-956.
23. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-Associated neurocognitive disorders. Neurology. 2007; 69: 1789-1799.
24. Dewey J, Hana G, Russell T, et al. Reliability and validity of MRI-based automated volumetry software relative to auto-Assisted manual measurement of subcortical structures in HIV-infected patients from a multisite study. NeuroImage. 2010; 51: 1334-1344.
25. Leow AD, Yanovsky I, Chiang MC, et al. Statistical properties of Jacobian maps and the realization of unbiased large-deformation nonlinear image registration. IEEE Trans Med Imaging. 2007; 26: 822-832.
26. Gutman B, Svarer C, Leow A, et al. Creating Unbiased Minimal Deformation Templates for Brain Volume Registration. Barcelona, Spain: Organization for Human Brain Mapping 2010.
27. Jahanshad N, Valcour VG, Nir TM, et al. Disrupted brain networks in the aging HIV+ population. Brain Connect. 2012; 2: 335-344.
28. Langers DR, Jansen JF, Backes WH. Enhanced signal detection in neuroimaging by means of regional control of the global false discovery rate. Neuroimage. 2007; 38: 43-56.
29. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc. 1995; 57: 289-300.
30. Nir TM, Jahanshad N, Busovaca E, et al. Mapping white matter integrity in elderly people with HIV. Hum Brain Mapp. 2014; 5: 975-992.
31. Nestor SM, Rupsingh R, BorrieM, et al. Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database. Brain. 2008; 131: 2443-2454.
32. Hua X, Leow AD, Parikshak N, et al. Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects. NeuroImage. 2008; 43: 458-469.
33. Kallianpur KJ, Shikuma C, Kirk GR, et al. Peripheral blood HIV DNA is associated with atrophy of cerebellar and subcortical gray matter. Neurology. 2013; 80: 1792-1799.
34. Gongvatana A, Schweinsburg BC, Taylor MJ, et al. White matter tract injury and cognitive impairment in human immunodeficiency virusinfected individuals. J Neurovirol. 2009; 15: 187-195.
35. Westlye LT, Reinvang I, Rootwelt H, et al. Effects of APOE on brain white matter microstructure in healthy adults. Neurology. 2012; 79: 1961-1969.
36. Song SK, Sun SW, Ramsbottom MJ, et al. Dysmyelination revealed through MRI as increased radial (but unchanged axial) diffusion of water. Neuroimage. 2002; 17: 1429-1436.
37. Soontornniyomkij V, Umlauf A, Chung SA, et al. HIV protease inhibitor exposure predicts cerebral small vessel disease. AIDS. 2014; 28: 1297-1306.
38. Lahoz C, Schaefer EJ, Cupples LA, et al. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis. 2001; 154: 529-537.
39. Holtzman DM, Herz J, Bu G. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med. 2012: 2: a006312.
40. Pulliam L. HIV regulation of amyloid beta production. J Neuroimmune Pharmacol. 2009; 2: 213-217.
41. Soontornniyomkij V, Moore DJ, Gouaux B, et al. Cerebral beta-Amyloid deposition predicts HIV-Associated neurocognitive disorders in APOE epsilon4 carriers. AIDS. 2012; 26: 2327-2335.